Introduction {#s1}
============

Colorectal cancer (CRC) is one of the most prevalent malignancies, ranking as the second leading cause of cancer-induced death worldwide ([@B5]). According to global statistics, it is estimated that CRC disease will affect more than 2.2 million new patients and will cause 1.1 million cancer deaths by 2030 ([@B2]). In the United States, the number of new cases of CRC reached 145,600, and the number of deaths reached 51,020 in 2019 ([@B39]). In recent years, despite advances in diagnosis and treatment of CRC, any of the current therapies cannot offer an effective therapeutic outcome due to the poor prognosis and high recurrence rate. The mortality rates are still high and unacceptable ([@B17]; [@B35]). Therefore, there is an urgent need for new CRC therapies.

Quercetin (QUE), a bioactive component belonging to the natural flavonoids group, is distributed in fresh onions, fruits, and vegetables ([@B38]). Previous studies suggested a positive association between QUE intake and improved outcomes of several types of cancer treatment ([@B18]). Recently, intense attention has been paid to the chemo-preventive and anti-tumor functions of QUE on colon cancer and increasing experimental evidence verified these effects *in vivo* and *in vitro*. Moreover, extensive studies had reported that QUE has anti-cell proliferation, pro-apoptosis, anti-angiogenesis, and anti-metastasis effects on colon cancer ([@B9]). In addition, Maria et al. confirmed that the CB1 receptor mediated the anti-proliferative and pro-apoptotic of QUE effects in human colon cancer cell lines ([@B37]). A transcriptomics and proteomics research was conducted to characterize gene and protein changes occurring in the distal colon mucosa of rats supplemented with QUE; this further enriches the anti-cancer mechanism of QUE *in vitro* ([@B11]). Although multiple lines of studies demonstrated the efficacy of QUE, the exact mechanism of its anti-tumor effects in CRC remains unclear. Hence, more advanced tools with large-scale data are required for the deep interpretation of the problems.

Non-coding RNAs (ncRNAs) are an abundant class of RNAs that typically do not encode proteins but functionally regulate protein expression ([@B32]). As part of RNA--protein complexes in regulating gene expression, ncRNAs can be subdivided into several families based on their size and biogenesis pathways, including microRNAs (miRNAs, with \<200 nucleotides), long ncRNAs (lncRNAs, with a length \>200 bp), and circular RNAs (circRNAs, with a closed continuous loop) ([@B6]; [@B43]; [@B42]). These different ncRNAs are further classified based on sequence or structure conservation, subcellular localization and function, and association with annotated protein-coding genes and other DNA elements of known function ([@B40]). Accumulating evidence indicated that ncRNAs are involved in a remarkable variety of biological functions. Moreover, multiple lines of evidence have linked ncRNA mutations and dysregulation with various human diseases, especially cancers. Colon cancer is characterized by genetic and epigenetic modifications; thus, ncRNAs were emerging key regulators of gene expression under colon cancer ([@B20]; [@B15]; [@B53]; [@B29]). [@B16] profiled at least 37 differentially expressed miRNAs between CRC tissues and normal colon mucosa. [@B19] detected that 21 miRNAs differentially expressed in serum of CRC patients may be applied to identify colon cancer patients at an early stage of the disease. The expression profile of circRNA in CRC tissues has also been identified, which could be used as new biomarkers for prognosis and diagnosis of CRC ([@B3]). A recent report has summarized that the lncRNA regulating cancer cell proliferation, migration, and apoptosis might also serve as biomarkers for CRC diagnosis and prognosis, including LOC285194, RP11-462C24.1, BANCR, NR_034119, NR_029373, lncRNA-AFAP1-AS1, and NR_026817.79 ([@B10]).

However, few of transcriptomes concerned about the transcriptomic effect of QUE intervention against CRC were published, and various questions remain unanswered with respect to the ncRNAs in response to QUE treatment. Thus, the whole transcriptome sequencing technique was used to profile the coding transcriptome and ncRNAs changes occurred in CRC cell response to QUE treatment. Additionally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to explore the biological roles and potential signaling pathways of these differentially expressed mRNA and ncRNAs. Moreover, co-expression networks were constructed based on these sequencing data and bioinformatics analysis. These results could provide novel insights into the molecular basis of QUE in treating CRC.

Materials and Methods {#s2}
=====================

Cell Lines and Cell Culture {#s2_1}
---------------------------

The human colon cancer cell line (HCT-116) was purchased from Shanghai Institutes for Biological Sciences (SIBS, Shanghai, China). The cells were cultured in Dulbecco's modified Eagle's medium contained in tissue culture flasks. The medium was supplemented with 10% fetal bovine serum (FBS), antibiotics, and 1% glutamine. The cells were cultured at 37°C under a humidified atmosphere containing 5% CO~2~ and 95% air.

Cell Viability and Proliferation Assay {#s2_2}
--------------------------------------

HCT-116 cells were seeded in 96-well plates and intervened with various concentrations of QUE (100 μΜ, 150 μΜ, 200 μΜ, and 250 μΜ) for 24, 48, and 72 h. Following incubation, cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega Corporation, Madison, USA, 0000328878). IC~50~ values were calculated by interpolation from dose--response curves.

Cell Apoptosis Detection {#s2_3}
------------------------

In brief, HCT-116 cells were seeded in six-well plates at a density of 4 × 10^4^/well and incubated with QUE at different concentrations (100, 150, and 200 μΜ) for 72 h. Then, cells were collected by centrifugation, washed with phosphate-buffered saline, and resuspended with 400 µl of buffer. After that, cell suspensions were stained with Annexin V-FITC and propidium iodide (PI) according to the manufacturer's instruction. At last, cell apoptosis detection was performed by a flow cytometer (Shanghai Pudi Biotechnology Co., Ltd., BDFACS Calibur) and analyzed by FlowJo 7.6.

RNA Extraction and Quality Monitoring {#s2_4}
-------------------------------------

Transcriptomic analysis was performed on untreated HCT-116 cells and HCT-116 cells treated with 150 μΜ QUE for 48 h. At first, total RNA of HCT-116 cells was extracted from three independent experiments by Trizol reagent (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's protocol. RNA quantity and quality were measured by a spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) and the Agilent 2100 Bioanalyzer (Agilent Technologies).

RNA Library Construction, Quality Control, and Sequencing {#s2_5}
---------------------------------------------------------

The small RNA library (sRNA library) was constructed according to the manufacturer's instruction of TrueSeq small RNA library prep kit (Illumina San Diego CA, USA), and 2.5 ng RNA per sample was used as the initial amount. The T4 RNA Ligase 1 was ligated to the 3′ end of the RNA, followed by the ligation of T4 RNA Ligase 2 (truncated) to the 5′ adapter. After that, the RNA was reverse transcribed to synthesize cDNA. Finally, small RNA libraries were obtained by screening these recovered fragments using gel separation technology. In the construction of lncRNA library (chain-specific library for removal of ribosomal RNA), the epicenter Ribo-ZeroTM kit was used to remove the ribosomal RNA. Then, rRNA-depleted RNA was fragmented and used as a template to construct the cDNA library. The qualities of the libraries were further tested following these steps: 1) Initial quantification was performed using Qubit 2.0, and the insert size of the library was tested using Agilent 2100. 2) The Q-PCR method was used to accurately quantify the effective concentration of the library (effective library concentration \> 2 nM). After the libraries' quality tests were passed, different libraries performed pooling according to the amount of target data, followed by sequencing on the Illumina HiSeq platform.

Data Processing {#s2_6}
---------------

Based on Sequencing-By-Synthesis (SBS) technology, the Illumina HiSeq high-throughput sequencing platform sequenced cDNA libraries to produce a large amount of high-quality data, i.e., raw data. In order to ensure the accuracy of information analysis, quality control of the original data is required to obtain a high-quality sequence, which is clean reads. The exclusion criteria for quality control of the original sequence measured by the deribosomal library included the following: 1) low-quality data, 2) reads containing jointed-sequence, and 3) reads containing N (undetermined base information) ratio greater than 5%. The exclusion criteria for quality control of the original sequence measured by the sRNA library included the following: 1) low-quality data, 2) reads containing N ratio greater than 10%, 3) reads without 3′ linker sequence, and 4) sequences shorter than 15 or longer than 35 nucleotides.

The targets for miRNAs were predicted using miRanda ([@B4]) and targetscan ([@B28]). The targets for lncRNAs were predicted based on position relationship (within 100 kb of lncRNA) and Pearson correlation coefficient (when sample size \>5, the absolute value of correlation \>0.9, and *p* value \< 0.01) between lncRNA and mRNA. The source genes for circRNAs were acquired according to the position of the circRNA sequence; namely, the gene on which the circRNA sequence was located was deemed as its source gene.

Quantitative Real-Time PCR Validation {#s2_7}
-------------------------------------

To validate the expression levels of the selected lncRNAs, miRNAs, circRNAs, and mRNAs by quantitative real-time polymerase chain reaction (qRT-PCR), RNA samples from the untreated HCT-116 cells and HCT-116 cells treated with 150 μΜ QUE for 48 h were collected. Total RNA was isolated by using the Trizol reagent (Invitrogen, USA), and then reverse-transcribed into cDNA using SuperScript III Reverse Transcriptase (Invitrogen, USA) according to the manufacturer's instruction. A Gene Amp PCR System 9700 (Applied Biosystems, USA) and 2× PCR Master Mix (Arraystar, USA) were used to perform qRT-PCR in accordance with the manufacturer's instructions. The circRNA, lncRNA, and mRNA expression levels were normalized to β-actin (Human), an endogenous reference transcript, and calculated using the standard curve-based method ([@B27]). The expression levels of the selected miRNAs, being normalized against the U6 (human), were calculated by the 2^−ΔΔCt^ method using untreated control as the calibrator ([@B31]). The sequences of all primers are shown in [**Table 1**](#T1){ref-type="table"}. The data represent the means of three experiments.

###### 

Primers designed for qRT-PCR validation of candidate miRNAs, mRNAs, circRNAs and lncRNAs.

                           Forward primer                  Reverse Primer                 Tm (°C)   Product length
  ------------------------ ------------------------------- ------------------------------ --------- ----------------
  β-actin                  5′GTGGCCGAGGACTTTGATTG3′        5′CCTGTAACAACGCATCTCATATT3′    60        73
  U6                       5′GCTTCGGCAGCACATATACTAAAAT3′   5′CGCTTCACGAATTTGCGTGTCAT3′    60        89
  hsa-miR-125b-2-3p        5′GGGGTCACAAGTCAGGCTCT3′        5′GTGCGTGTCGTGGAGTCG3′         60        64
  hsa-miR-338-3p           5′GGGGGTCCAGCATCAGTGA3′         5′GTGCGTGTCGTGGAGTCG3′         60        65
  hsa-miR-320b             5′AGCTGGGTTGAGAGGGCAA3′         5′GTGCGTGTCGTGGAGTCG3′         60        57
  hsa-miR-5096             5′GGGGAGTTTCACCATGTTG3′         5′CAGTGCGTGTCGTGGAGTC3′        60        66
  LRG1                     5′GGAGCAGACAGCGACCAAA3′         5′CAGCAGCAGCAGGAACAGAG3′       60        74
  AZGP1                    5′GGAGACCCTGAAAGACATCGTG3′      5′AACCAAACCTTCCCTGCAATAC3′     60        74
  TRIM29                   5′ATGCGCCACGTTGAGAAGAT3′        5′CGAGGGCTGGTATGATGTCC3′       60        204
  APOBEC3G                 5′CATCGTGACCAGGAGTATGAGG3′      5′AAGTAGTAGAGGCGGGCAACA3′      60        137
  2:206841107\|206881891   5′GAGCAAGCAGATGAGGCAAAG3′       5′GGTGATGTGACAATCCAGGTAGC3′    60        126
  2:206866697\|206881891   5′AGGCAAAGCACACTCTGAAGC3′       5′GGGAACATCTGGCAGGTCTAA3′      60        116
  ENST00000313807          5′TCAAATCTCCCTGGGTCTCC3′        5′TATCCAAAGGCATCGTCTATCT3′     60        217
  MSTRG.128888.1           5′CAAAGGTCACAGACATTCAGGCA3′     5′CCAGTTCTTACACCTTCGGTCATC3′   60        242

GO and KEGG Pathway Analysis {#s2_8}
----------------------------

To better understand the biological functions and potential mechanisms of ncRNAs and mRNAs in the mechanism of QUE acting on CRC, we applied GO enrichment and KEGG pathway analyses on these differentially expressed mRNAs (DEmRNAs), source genes of differentially expressed circRNAs (DEcircRNAs), predicted target genes of differentially expressed miRNAs (DEmiRNAs), and predicted target genes of differentially expressed lncRNAs (DElncRNAs). Briefly, GO analyses ([www.geneontology.org](www.geneontology.org)) consisted of three components: biological process (BP), cellular component (CC), and molecular function (MF). KEGG analyses were carried to investigate the potential significant pathways (<http://www.genome.jp/kegg/>).

Construction of Co-expression Network {#s2_9}
-------------------------------------

CircRNA, lncRNA, and mRNA could inhibit target gene regulation of miRNA to indirectly regulate gene expression, serving as a miRNA sponge to bind miRNA competitively with its binding sites, which was called competing endogenous RNA (ceRNA). Based on the theory of ceRNA, the circRNA--miRNA--mRNA and lncRNA--miRNA--mRNA network were constructed and visually displayed using the Cystoscope software V3.5.0 (San Diego, CA, USA), as previous described. Different shapes and colors represent different RNA types and regulated relationships, respectively.

Statistical Analysis {#s2_10}
--------------------

Statistical differences were determined by using SPSS 22.0 software. A *p* value less than 0.05 was considered to be significant. For sequencing data, we analyzed DE ncRNAs and DEmRNAs using DEseq ([@B1]) software, with *p* \< 0.05 and \|log2 (fold change)\| \> 2 as screening criteria.

Results {#s3}
=======

QUE Inhibits the Proliferation of HCT116 Cells {#s3_1}
----------------------------------------------

As shown in [**Figure 1A**](#f1){ref-type="fig"}, QUE at concentrations of 100, 150, 200, and 250 μΜ was used to treat HCT-116 cells for 24, 48, and 72 h, respectively, and the results showed that the viability of HCT-116 cells was markedly reduced by QUE, in both a dose- and time-dependent manner. As shown in [**Figure 1B**](#f1){ref-type="fig"}, the IC~50~ values for QUE were 220.1, 179.7, and 143.23 μΜ.

![Effect of QUE on the proliferation of HCT116 cells by MTS assay. HCT116 cells were treated with quercetin at the indicated concentrations for 24, 48, and 72 h. QUE suppresses viability of HCT116 cells **(A)**. IC~50~ values for QUE at 24, 48, and 72 h in HCT116 cells **(B)**. Data are presented as the mean ± SD from at least three independent experiments. **Abbreviation:** QUE, quercetin.](fphar-10-00798-g001){#f1}

QUE Induces Apoptosis in HCT-116 Cells {#s3_2}
--------------------------------------

Cells were treated with 100, 150, and 200 μM QUE for 72 h and stained with Annexin V-FITC and PI for the analysis of apoptosis. As shown in [**Figure 2**](#f2){ref-type="fig"}, the percentage of apoptotic cells was significantly increased in a dose-dependent manner after QUE treatment. Taken together, these results clearly demonstrated QUE-induced apoptosis of HCT-116 cells.

![Effect of QUE at different concentrations on apoptosis of HCT116 cells as detected by flow cytometry. **(A)** Control; **(B)** 100 µM; **(C)** 150 µM; **(D)** 200 µM. **(E)** The percentage of apoptotic cells was presented as the mean ± SD of three independent experiments, \**P* \< 0.05 vs. control; one-way ANOVA, followed by Dunnett's *post hoc* test. **Abbreviations:** QUE, quercetin; CON, control.](fphar-10-00798-g002){#f2}

Sequencing and Mapping of the Transcriptome {#s3_3}
-------------------------------------------

The cDNA and sRNA libraries of cell samples from three groups of untreated HCT-116 cells and three groups of QUE-treated HCT-116 cells were sequenced. Moreover, counts of clean reads and mapped ratio of sequencing data are shown in [**Table 2**](#T2){ref-type="table"}.

###### 

Deep RNA sequencing of subjects.

  Sample ID   LncRNA + mRNA + cirRNA sequencing   miRNA sequencing                                           
  ----------- ----------------------------------- ------------------ -------- ---------- ---------- -------- --------
  QUE         QUE-1                               136940730          93.8     76.42%     29589490   99.05    54.90%
  QUE-2       142365786                           94.88              65.82%   33463913   99.11      60.02%   
  QUE-3       116119138                           94.98              58.93%   28926985   99.22      54.72%   
  CON         CON-1                               117429248          94.4     78.85%     39189854   99.16    63.70%
  CON-2       130625532                           95.01              78.88%   51489576   99.10      64.54%   
  CON-3       118788322                           94.63              77.92%   52661569   99.11      68.34%   

QUE-1, QUE-2, and QUE-3 represent three groups of HCT-116 cells treated with QUE. CON-1, CON-2, and CON-3 represent three groups of untreated HCT-116 cells.

QUE, quercetin; CON, control.

Differentially Expressed ncRNAs and mRNAs {#s3_4}
-----------------------------------------

Information of the top 20 up-regulated and 20 down-regulated lncRNAs, circRNAs, miRNAs, and mRNAs in the QUE-treated cells compared with the untreated cells are listed in [**Tables 3**](#T3){ref-type="table"}--[**6**](#T6){ref-type="table"}. Volcano plot, MA plot, and Unsupervised clustering analysis were applied to exhibit DEncRNA and DEmRNA expression profiles between the QUE-treated cells and the untreated cells. [**Figures 3A--D**](#f3){ref-type="fig"} shows in detail the volcano plot of DEmiRNA, DElncRNA, DEcircRNA, and DEmRNA expression profiles, respectively. [**Figures 3E--H**](#f3){ref-type="fig"} indicates the MA plot of DEmiRNA, DElncRNA, DEcircRNA, and DEmRNA expression profiles, respectively. The Unsupervised clustering analysis showing the expression profiles of the top 20 up- and down-regulated DEmiRNAs, DElncRNAs, DEcircRNAs, and DEmRNAs is illustrated in [**Figures 3I--L**](#f3){ref-type="fig"}.

###### 

The top 20 up- and down-regulated miRNAs.

  Name                QUE-1      QUE-2      QUE-3      CON-1      CON-2      CON-3      *P* value   log2FC    Regulated
  ------------------- ---------- ---------- ---------- ---------- ---------- ---------- ----------- --------- -----------
  hsa-miR-219a-2-3p   47.8313    38.034     41.278     0          0.3117     0.0359     9.24E−14    7.8505    Up
  novel_miR_20        10.7557    10.9283    23.3697    0.1065     0.1417     0.1435     2.33E−10    6.0999    Up
  hsa-miR-338-3p      5.188      3.1838     5.3344     0          0          0.1793     2.87E−09    5.3058    Up
  novel_miR_710       110        1155.4     265.3222   5.1665     12.5832    8.141      0.01733     5.0431    Up
  hsa-miR-383-5p      2.2777     1.4628     2.0321     0.1598     0          0          2.09E−08    4.8215    Up
  hsa-miR-30c-2-3p    1.0123     1.0326     1.9051     0          0.1417     0          2.30E−07    4.1288    Up
  novel_miR_873       12.4007    22.8032    2.0321     0.1065     0.4534     0.7173     0.005265    4.0298    Up
  hsa-miR-433-3p      4.6819     4.3885     3.4292     0.5326     0          0.0717     3.95E−07    3.9197    Up
  novel_miR_885       790.6      1696.2     3132.3     108.4427   88.5639    54.7634    0.000332    3.7825    Up
  hsa-miR-4485-3p     3.5431     5.9374     16.3842    0.4261     0.6235     0.251      0.011976    3.6025    Up
  hsa-miR-1290        12.2742    57.8255    45.0883    2.024      2.2672     1.6139     0.000134    3.5209    Up
  hsa-miR-6797-3p     1.0123     1.5489     1.5241     0.2131     0          0.0359     8.96E−09    3.5168    Up
  hsa-miR-504-5p      11.2619    9.8957     11.4308    0.9055     0.9069     0.251      6.33E−05    3.4046    Up
  novel_miR_301       3.29       6.0235     8.3826     0.6392     0.3968     0.2869     6.23E−05    3.0738    Up
  hsa-miR-338-5p      9.6169     10.6702    10.7958    0.9587     1.3603     0.251      0.000364    2.9959    Up
  novel_miR_841       2.0246     4.6467     3.4292     0.3728     0.4251     0.0359     3.64E−05    2.9880    Up
  novel_miR_684       334.9454   508.6404   1209.8     60.1335    69.8875    41.6374    0.007656    2.8662    Up
  hsa-miR-204-5p      7.3392     6.6258     8.1286     0.6924     0.9352     0.7531     0.001859    2.5244    Up
  hsa-miR-125b-2-3p   6.0738     2.4094     4.1913     0.9055     0.2834     0.3586     0.017467    2.5090    Up
  hsa-miR-5096        3.6696     2.4954     1.3971     0.2663     0.4534     0.1793     0.025683    2.4837    Up
  hsa-miR-1257        0          0.2581     0.381      3.1958     2.2672     5.3078     0.000527    −4.9679   Down
  hsa-miR-143-3p      167.4094   148.608    158.3804   222.4781   171.573    298.3478   0.046004    −1.2611   Down
  hsa-miR-203a-3p     1965.3     2110.8     2034.6     2944.9     3156.6     3924.2     0.004354    −1.4364   Down
  hsa-miR-21-5p       227730     184152     145194     259839     384154     139555     0.030963    −1.0935   Down
  hsa-miR-26a-2-3p    1.0123     1.1186     0.8891     2.0772     2.9191     5.4154     0.030104    −2.5689   Down
  hsa-miR-33a-3p      3.6696     3.0978     2.0321     5.6458     5.4697     6.4913     0.024884    −1.6717   Down
  hsa-miR-3684        1.0123     1.2047     0.7621     2.1305     1.332      2.0801     0.030702    −1.5871   Down
  hsa-miR-3942-5p     1.5185     0.6884     0.254      1.8109     1.502      3.2277     0.035983    −2.0560   Down
  hsa-miR-4454        8.9842     9.3794     2.9212     9.4275     22.1055    11.8349    0.021729    −1.6904   Down
  hsa-miR-4484        0          0.6884     1.2701     1.4381     3.2025     1.5421     0.0045      −2.4779   Down
  hsa-miR-451a        18.2214    17.6402    18.4163    155.3671   117.6128   152.9216   5.91E−07    −3.6597   Down
  hsa-miR-4671-3p     0.3796     0.9465     0.508      1.4381     1.0486     2.2235     0.033673    −2.1636   Down
  hsa-miR-486-5p      16.5764    20.0496    31.2443    138.8024   117.3578   118.8514   1.12E−05    −3.1721   Down
  hsa-miR-493-3p      0.8858     1.6349     1.1431     2.0772     2.0122     2.4746     0.03867     −1.5905   Down
  hsa-miR-6505-5p     4.0492     1.9791     4.0643     7.6698     7.7653     4.8057     0.018848    −1.6118   Down
  hsa-miR-7974        35.6836    83.2962    99.4482    491.8272   206.0634   370.2898   1.33E−05    −3.0231   Down
  novel_miR_343       0.5062     1.1186     0.127      1.5979     1.0203     0.7531     0.029758    −1.5914   Down
  novel_miR_379       11.3884    14.8006    11.9389    62.3173    20.6035    37.1904    0.00321     −2.3063   Down
  novel_miR_895       1.645      2.4954     1.7781     7.8829     6.5466     9.5755     0.00074     −2.7583   Down

QUE-1, QUE-2, and QUE-3 represent three groups of HCT-116 cells treated with QUE. CON-1, CON-2, and CON-3 represent three groups of untreated HCT-116 cells.

QUE, quercetin; CON, control.

###### 

The top 20 up- and down-regulated circRNAs.

  NAME                      QUE-1    QUE-2    QUE-3    CON-1    CON-2    CON-3    *P* value   log2FC    Regulated
  ------------------------- -------- -------- -------- -------- -------- -------- ----------- --------- -----------
  2:61485768\|61490776      2.8997   3.8419   3.5119   0        0        0        1.78E−11    Inf       Up
  14:65615978\|65629606     1.5727   1.328    1.6389   0        0        0        2.77E−06    Inf       Up
  17:44154556\|44155411     0.983    0.9012   1.2877   0        0        0        9.08E−05    Inf       Up
  12:45926142\|45928859     1.0321   1.1858   0.4683   0        0        0        0.000209    Inf       Up
  10:127106231\|127127764   0.9338   0.7589   1.1121   0        0        0        0.000246    Inf       Up
  1:12275825\|12278038      0.5406   1.328    0.8195   0        0        0        0.00025     Inf       Up
  1:231616644\|231618059    0.7372   0.7115   1.2292   0        0        0        0.000382    Inf       Up
  14:69116366\|69122360     0.7372   0.4743   1.3462   0        0        0        0.000599    Inf       Up
  12:70507895\|70522630     0.6881   0.5217   1.1706   0        0        0        0.000865    Inf       Up
  9:91883258\|91887113      0.7864   0.6166   0.7024   0        0        0        0.001363    Inf       Up
  12:116096669\|116111512   0.5898   0.8063   0.5853   0        0        0        0.001712    Inf       Up
  2:241704653\|241712071    0.5406   0.7115   0.7024   0        0        0        0.002002    Inf       Up
  22:46972332\|46974399     0.4915   0.332    2.2242   0        0        0        0.002672    Inf       Up
  15:101366196\|101370523   0.6389   0.4743   0.6439   0        0        0        0.003471    Inf       Up
  X:24809898\|24843677      0.3932   0.4743   0.8195   0        0        0        0.004631    Inf       Up
  12:122788758\|122813419   0.344    0.8063   0.4097   0        0        0        0.004876    Inf       Up
  3:49699476\|49700709      0.5406   0.5692   0.4683   0        0        0        0.005033    Inf       Up
  1:245915530\|245929937    0.8355   0.2846   0.4683   0        0        0        0.005185    Inf       Up
  3:56627037\|56628614      0.3932   0.4269   0.8195   0        0        0        0.00532     Inf       Up
  8:128186556\|128193682    0.3932   0.4269   0.8195   0        0        0        0.00532     Inf       Up
  14:34862044\|34862322     0        0        0        1.4376   0.9824   1.0778   2.03E−05    \#NAME?   Down
  17:72592203\|72649268     0        0        0        0.9776   0.7756   0.5673   0.000559    \#NAME?   Down
  10:30026103\|30029866     0        0        0        0.805    2.3784   0.2836   0.000642    \#NAME?   Down
  19:311845\|313643         0        0        0        0.23     1.4477   0.5673   0.001014    \#NAME?   Down
  8:93786223\|93822563      0        0        0        0.575    0.6204   0.9076   0.001214    \#NAME?   Down
  2:3545701\|3552308        0        0        0        0.46     0.7756   0.7942   0.001532    \#NAME?   Down
  15:69210316\|69261329     0        0        0        0.575    0.6721   0.7374   0.001611    \#NAME?   Down
  1:180824753\|180825344    0        0        0        0.7475   0.6204   0.5673   0.001657    \#NAME?   Down
  1:246591512\|246591941    0        0        0        0.46     0.5687   0.5673   0.004485    \#NAME?   Down
  15:40628070\|40650819     0        0        0        0.46     0.8273   0.1135   0.007056    \#NAME?   Down
  11:110136663\|110137414   0        0        0        0.575    0.2585   0.5673   0.007095    \#NAME?   Down
  1:43920404\|43920928      0        0        0        0.4025   0.2068   0.7374   0.008786    \#NAME?   Down
  16:72811577\|72812038     0        0        0        0.23     0.7756   0.3404   0.008888    \#NAME?   Down
  1:52396046\|52397863      0        0        0        0.4025   0.6204   0.2269   0.010575    \#NAME?   Down
  16:68859884\|68880630     0        0        0        0.2875   0.517    0.4538   0.010939    \#NAME?   Down
  7:154975696\|154998784    0        0        0        0.4025   0.4653   0.2836   0.01359     \#NAME?   Down
  11:17959470\|18010139     0        0        0        0.2875   0.3102   0.5105   0.015873    \#NAME?   Down
  X:131736127\|131794466    0        0        0        0.4025   0.1551   0.4538   0.019845    \#NAME?   Down
  X:131364749\|131399704    0        0        0        0.115    0.5687   0.2836   0.021384    \#NAME?   Down
  2:196912882\|196920150    0        0        0        0.4025   0.2585   0.2269   0.026239    \#NAME?   Down

QUE-1, QUE-2, and QUE-3 represent three groups of HCT-116 cells treated with QUE. CON-1, CON-2, and CON-3 represent three groups of untreated HCT-116 cells.

QUE, quercetin; CON, control.

###### 

The top 20 up- and down-regulated lncRNAs.

  \#ID              QUE-1      QUE-2      QUE-3      CON-1    CON-2    CON-3     *P* value   log2FC     Regulated
  ----------------- ---------- ---------- ---------- -------- -------- --------- ----------- ---------- -----------
  MSTRG.56057.6     1.011199   0.564535   0.780016   0        0        0         1.42E−06    Inf        Up
  MSTRG.12859.2     0.491669   0.61381    0.90822    0        0        0         2.09E−06    Inf        Up
  MSTRG.3610.5      0.86471    0.78501    0.372459   0        0        0         7.70E−06    Inf        Up
  MSTRG.218758.4    0.687719   1.616394   0.17021    0        0        0         9.68E−06    Inf        Up
  ENST00000499601   0.524056   0.821801   1.320079   0        0        0         1.24E−05    Inf        Up
  ENST00000412485   0.541436   0.442815   0.133381   0        0        0         1.61E−05    Inf        Up
  MSTRG.71538.4     0.362249   0.312796   0.115272   0        0        0         2.42E−05    Inf        Up
  MSTRG.171055.1    1.421666   0.22262    0.939521   0        0        0         2.45E−05    Inf        Up
  MSTRG.105262.2    0.845969   0.384586   0.337466   0        0        0         3.03E−05    Inf        Up
  MSTRG.81301.2     0.314015   0.455942   0.181373   0        0        0         3.19E−05    Inf        Up
  MSTRG.157135.4    0.370713   0.661509   0.264077   0        0        0         4.17E−05    Inf        Up
  ENST00000622389   0.417104   0.54098    0.30028    0        0        0         8.36E−05    Inf        Up
  MSTRG.15507.1     0.29734    0.287354   0.132048   0        0        0         0.000133    Inf        Up
  ENST00000453837   0.076754   0.195031   0.132529   0        0        0         0.000176    Inf        Up
  ENST00000608028   0.133745   0.067203   0.059525   0        0        0         0.000225    Inf        Up
  MSTRG.125001.5    0.334434   0.361555   0.408215   0        0        0         0.000265    Inf        Up
  MSTRG.25207.1     0.170071   0.553006   0.210474   0        0        0         0.000266    Inf        Up
  MSTRG.12814.2     0.381843   0.453598   0.957113   0        0        0         0.000396    Inf        Up
  MSTRG.60738.1     0.090811   0.30324    0.296676   0        0        0         0.000415    Inf        Up
  MSTRG.50481.1     0.481522   0.216593   0.167346   0        0        0         0.000578    Inf        Up
  MSTRG.206015.1    0          0          0          0.8716   0.9477   1.1035    1.61E−06    \#NAME?    Down
  MSTRG.97738.1     0          0          0          0.1847   0.4755   0.3154    0.000217    \#NAME?    Down
  MSTRG.81716.2     0          0          0          0.2771   0.2757   0.4464    0.000119    \#NAME?    Down
  MSTRG.145759.2    0          0          0          0.4361   0.3396   0.135     2.09E−06    \#NAME?    Down
  MSTRG.60750.1     0          0          0          0.5182   0.6108   0.3925    1.34E−09    \#NAME?    Down
  ENST00000584327   0          0          0          3.0625   1.5157   4.1065    1.19E−09    \#NAME?    Down
  ENST00000531381   0          0          0          0.1968   0.1891   0.1018    1.19E−06    \#NAME?    Down
  ENST00000434051   0          0          0          0.1172   0.0638   0.0642    2.69E−06    \#NAME?    Down
  MSTRG.173667.4    1.7892     1.5229     2.3347     1.5777   354.65   123556    0.010557    −15.0164   Down
  MSTRG.34086.4     0.0033     0.0004     0          1.2649   1.1295   0.714     3.13E−09    −7.4146    Down
  ENST00000400362   0.0271     0          0          1.9207   0.2462   0.727     4.26E−05    −7.0340    Down
  MSTRG.11657.2     0.5142     0          0          0        9.3146   15.1451   0.005018    −6.5397    Down
  ENST00000534914   0.0495     0.1393     0          0.6644   2.3301   1.8312    0.000169    −5.4299    Down
  MSTRG.70784.4     0          0.0129     0.005      0.1356   0.1773   0.1709    6.48E−05    −4.8623    Down
  ENST00000602806   0.0228     0.0614     0          0.6543   0.3518   0.6894    0.00142     −4.6659    Down
  ENST00000416742   0          0.0165     0          0.1446   0.0889   0.0773    0.001011    −4.6632    Down
  MSTRG.202069.1    0          0          0.0392     0.1394   0.3821   0.3348    0.000617    −4.6500    Down
  MSTRG.1953.2      0.4877     0.4417     0.422      7.8476   4.2212   6.9376    2.10E−05    −4.2371    Down
  MSTRG.202339.1    0          0.0958     0          0.2168   0.5654   0.2458    0.00507     −4.1651    Down
  MSTRG.13489.1     0.3488     0          0          0.8859   1.1009   1.6577    0.002828    −4.1369    Down

QUE-1, QUE-2, and QUE-3 represent three groups of HCT-116 cells treated with QUE. CON-1, CON-2, and CON-3 represent three groups of untreated HCT-116 cells.

QUE, quercetin; CON, control.

###### 

The top 20 up- and down-regulated mRNAs.

  Gene Symbol       QUE-1     QUE-2     QUE-3     CON-3      CON-2      CON-1      *P* value   log2FC    Regulated
  ----------------- --------- --------- --------- ---------- ---------- ---------- ----------- --------- -----------
  RP11-385D13.1     0.459     0.5438    0.1785    0.003      0          0          1.82E−12    7.9515    Up
  CTD-2410N18.5     40.0383   37.9792   2.5737    0.15       0.2501     1.9876     0.001324    4.4775    Up
  CXCL8             41.3213   20.8464   35.8399   1.6461     1.6596     2.5119     2.21E−08    3.9679    Up
  IL1RL1            0.4132    0.5353    0.9505    0.0603     0.0438     0.0062     1.53E−05    3.8184    Up
  EFCAB8            0.2146    0.4772    1.0995    0.0334     0.2802     0.0354     0.032473    3.7396    Up
  ACRC              2.2348    1.6744    2.5938    0.3101     0.0706     0.273      1.27E−07    3.0842    Up
  PAPPA2            0.3623    0.3721    0.5551    0.0637     0.0413     0.0333     1.39E−05    3.0253    Up
  TUSC3             2.2369    3.4756    2.6733    0.1932     0.236      0.1381     8.89E−07    2.9856    Up
  EID3              7.5414    6.3091    1.5003    1.0693     0.3949     0.263      0.001709    2.9377    Up
  MMP1              4.5738    1.8258    1.8633    0.1547     0.5818     0.223      0.001026    2.7474    Up
  AADAC             7.5793    4.7235    1.7104    1.4535     0.2833     0.2375     0.004429    2.7197    Up
  CYP4F3            12.0443   13.418    2.9752    1.8013     1.9014     0.9014     0.002971    2.7178    Up
  TCF19             0.6208    1.3387    0.4906    0.1369     0.1059     0.068      0.000219    2.6952    Up
  SLC6A12           0.3203    0.492     0.2143    0.1176     0.0204     0          0.004181    2.6693    Up
  C19orf38          2.3469    2.4262    4.4076    0.0535     0.3851     0.6403     0.001546    2.6459    Up
  DNAH12            0.1975    0.1442    0.0795    0.047      0.0126     0.0039     0.001165    2.6171    Up
  F2RL2             0.2827    0.6668    0.2137    0.2595     0.0422     0          0.004704    2.6124    Up
  LCT               0.3575    0.5997    0.6578    0.0971     0.049      0.0792     0.000116    2.6094    Up
  TF                2.1888    1.3499    0.1846    0.2799     0.061      0.1333     0.023651    2.5816    Up
  RP3-509I19.11     1.0911    1.3781    0.2671    0.1918     0.0291     0.1481     0.002571    2.5804    Up
  MAGEA6            0         0         0         1.724      0.7861     1.3604     6.11E−16    \#NAME?   Down
  TNFSF12-TNFSF13   0         0.0017    0         0.6983     1.3414     1.0317     6.26E−13    -9.1872   Down
  ANK1              0         0.0032    0.0038    0.1533     0.1184     0.1713     1.51E−08    -5.8831   Down
  PRR15L            0.1197    0.1226    0.0523    4.2384     6.2581     3.616      6.27E−15    -5.8829   Down
  BAG6              0.0169    0.0162    0.0173    1.064      0.2955     1.0986     1.23E−05    -5.7552   Down
  CD79B             0.0782    0.0434    0         0.7712     1.9847     1.7625     2.56E−06    -5.5688   Down
  KRT20             0.1982    0.0153    0         1.2966     1.2261     1.7863     1.50E−08    -4.6740   Down
  HLA-DRB1          0.766     0         0         1.7502     7.4034     4.9431     0.000763    -4.6398   Down
  AZGP1             0.0997    0         0.0493    0.7883     2.0076     1.042      8.16E−06    -4.5796   Down
  TTYH1             0.1016    0.0395    0         0.6519     1.6136     0.4997     0.001463    -4.5639   Down
  APOBEC3G          0.0512    0         0.0447    0.4597     0.7297     0.6744     1.52E−06    -4.4927   Down
  TNFRSF6B          21.537    22.9604   25.2291   236.6955   496.5118   462.5763   1.58E−06    -4.4295   Down
  PPP1R1B           0.0538    0.0211    0.144     1.2598     1.2531     2.2257     1.90E−05    -4.3329   Down
  S100A4            10.3514   11.3851   17.5961   152.9374   203.8127   277.9736   1.45E−06    -4.3277   Down
  SMIM5             0.0333    0.1101    0.0115    0.8277     1.2896     0.4922     0.001183    -4.3099   Down
  BST2              1.103     0.5154    1.395     7.6829     20.0847    14.3881    2.66E−05    -4.0807   Down
  PTGDS             0.1114    0.1319    0.0823    1.2747     1.8475     1.4403     8.25E−06    -4.0613   Down
  TRIM29            0.015     0.0954    0.0401    0.6682     0.8271     0.6418     1.71E−07    -4.0474   Down
  LRG1              0.1242    0.1033    0.2308    1.7433     1.6964     2.5503     2.71E−07    -3.9326   Down
  CLIC3             0.5461    0.6195    2.4456    7.4547     23.1513    16.0411    0.000133    -3.9134   Down

QUE-1, QUE-2, and QUE-3 represent three groups of HCT-116 cells treated with QUE. CON-1, CON-2, and CON-3 represent three groups of untreated HCT-116 cells.

QUE, quercetin; CON, control.

![RNA-seq reveals distinct expression pattern of miRNAs, lncRNAs, circRNAs, and mRNAs in HCT116 cells and QUE-treated HCT116 cells. **(A--D)** Volcano plot of DEmiRNAs, DElncRNAs, DEcircRNAs, and DEmRNAs expression profiles between HCT116 cells and QUE-treated HCT116 cells. **(E-H)** MA plot of DEmiRNAs, DElncRNAs, DEcircRNAs, and DEmRNAs expression profiles between HCT116 cells and QUE-treated HCT116 cells. **(I--L)** Unsupervised clustering analysis showing expression profiles of top 40 differentially expressed miRNAs, lncRNAs, circRNAs, and mRNAs between HCT116 cells and QUE-treated HCT116 cells. QUE-1, QUE-2, and QUE-3 represent three groups of HCT-116 cells treated with QUE. CON-1, CON-2, and CON-3 represent three groups of untreated HCT-116 cells. **Abbreviation:** QUE, quercetin. CON, control.](fphar-10-00798-g003){#f3}

In total, our project detected 15,755 lncRNAs, 25,843 mRNAs, 2,735 miRNAs, and 6,911 new circRNAs. As shown in [**Figure 4A**](#f4){ref-type="fig"}, there were 240 DElncRNAs (89 down-regulation and 151 up-regulation), 131 DEcircRNAs (37 down-regulation and 94 up-regulation), 83 DEmiRNAs (19 down-regulation and 64 up-regulation), and 1,415 DEmRNAs (901 down-regulation and 514 up-regulation) in the QUE-treated cells compared to the untreated cells, respectively. In an effort to further pinpoint the genes involved in the mechanism of QUE anti-CRC, we performed a global overlapping gene analysis. The intersections of DEmRNA, DEmiRNA--Target mRNA, DELncRNA--Target Trans.mRNA, and DEcircRNA--Hostgene are showed in [**Figure 4B**](#f4){ref-type="fig"}. This left us with six reliable core mRNAs validated by different platforms and across different institutions, including ENSG00000101187, ENSG00000111344, ENSG00000116183, ENSG00000125319, ENSG00000150637, and ENSG00000169035.

![Count of relative differential expressed ncRNAs and mRNAs in HCT116 cells and QUE-treated HCT116 cells. Histogram showing the number of up- and down-regulated ncRNAs and mRNAs. Green represents up-regulation, and red represents down-regulation **(A)**. Venn diagram showing the overlap number of DE-mRNA, DE-LncRNA-Target.TransmRNA, DE-miRNA-TargetmRNA, and DE-circRNA-Hostgene **(B)**. **Abbreviation:** QUE, quercetin.](fphar-10-00798-g004){#f4}

Expression Profile Validation {#s3_5}
-----------------------------

To validate the accuracy and reliability of the RNA sequencing results, a total of 12 dysregulated ncRNAs and mRNAs were selected for qRT-PCR analysis, including four miRNAs (hsa-miR-125b-2-3p, hsa-miR-338-3p, hsa-miR-320b, and hsa-miR-5096), four mRNAs (LRG1, AZGP1, TRIM29, and APOBEC3), two lncRNAs (ENST00000313807 and MSTRG.128888.1), and two circRNAs (2:206841107\|206881891 and 2:206866697\|206881891). As shown in [**Figure 5**](#f5){ref-type="fig"}, the results from sequencing data were in agreement with those from qRT-PCR in terms of the expression levels of the validated ncRNAs and mRNAs.

![The differential expression of ncRNAs and mRNAs was validated by quantitative real-time PCR (qRT-PCR). The data showed that the expression levels of the hsa-miR-125b-2-3p, hsa-miR-338-3p, hsa-miR-320b, hsa-miR-5096, circRNA 2:206841107\|206881891, and circRNA 2:206866697\|206881891 were up-regulated and that the LRG1, AZGP1, TRIM29, APOBEC3, lncRNA ENST00000313807, and lncRNA MSTRG.128888.1 were down-regulated in QUE-treated HCT116 cells relative to the HCT116 cells. The heights of the columns in the chart represent fold change. The qRT-PCR results were consistent with the RNA sequencing data. \**P* \< 0.05, QUE vs. CON. QUE represents HCT-116 cells treated with QUE. CON represents untreated HCT-116 cells. **Abbreviations:** QUE, quercetin. CON, control.](fphar-10-00798-g005){#f5}

GO Enrichment Analysis {#s3_6}
----------------------

Based on the GO enrichment analysis of the cis targeted genes of lncRNA ([**Figure 6A**](#f6){ref-type="fig"}), the most significantly enriched BP, CC, and MF were protein ADP-ribosylation, actin cytoskeleton, and RNA-directed DNA polymerase activity, respectively. Based on the GO enrichment analysis of the trans targeted genes of lncRNA ([**Figure 6B**](#f6){ref-type="fig"}), the most significantly enriched BP, CC, and MF were stimulatory C-type lectin receptor signaling pathway, spindle pole, and protein N-terminus binding, respectively. Based on the GO enrichment analysis of DEmRNAs ([**Figure 6C**](#f6){ref-type="fig"}), the most significantly enriched BP, CC, and MF were defense response to virus, apical plasma membrane, and structural molecule activity, respectively. Based on the GO enrichment analysis of source genes of DEcircRNAs ([**Figure 6D**](#f6){ref-type="fig"}), the most significantly enriched BP, CC, and MF were protein phosphorylation, nuclear matrix, and phospholipid binding, respectively. Based on the GO enrichment analysis of targeted genes of DEmiRNAs ([**Figure 6E**](#f6){ref-type="fig"}), the most significantly enriched BP, CC, and MF were positive regulation of apoptotic process, cell junction, and phospholipid binding, respectively.

![The GO enrichment analysis of the cis targeted genes of DE lncRNA **(A)**, the trans targeted genes of DE lncRNA **(B)**, DE mRNA **(C)**, hostgenes of DE cirRNA **(D)**, and targeted genes of DE miRNA **(E)**. The GO enrichment analysis provided a controlled vocabulary to describe the co-expressed genes of the differentially expressed ncRNAs and mRNA. The ontology covered three domains: biological process, cellular component, and molecular function. The abscissa represents the number of genes annotated in the GO term, the ordinate represents the GO term, and the color of the column represents the corrected *p* value. **Abbreviation:** GO, Gene Ontology.](fphar-10-00798-g006){#f6}

KEGG Pathway Enrichment Analysis {#s3_7}
--------------------------------

The most significantly enriched KEGG pathways are shown in [**Figure 7**](#f7){ref-type="fig"}. For the cis targeted genes of DElncRNA ([**Figure 7A**](#f7){ref-type="fig"}), alcoholism, systemic lupus erythematosus, and antigen processing and presentation were the most significant pathways for enrichment. For the trans targeted genes of DElncRNA ([**Figure 7B**](#f7){ref-type="fig"}), cell cycle, pyrimidine metabolism, and glycolysis/gluconeogenesis were the most significant enriched pathway. For the DEmRNAs ([**Figure 7C**](#f7){ref-type="fig"}), Alzheimer's disease, carbon metabolism, and biosynthesis of amino acids were the most significant enriched pathway. For the hostgenes of DEcircRNA ([**Figure 7D**](#f7){ref-type="fig"}), Fanconi anemia pathway, glycosaminoglycan biosynthesis--keratan sulfate, and DNA replication were the most significant enriched pathway. For the DE miRNAs ([**Figure 7E**](#f7){ref-type="fig"}), focal adhesion, cAMP signaling pathway, and miRNAs in cancer were the most significant enriched pathway. The main biochemical pathways and signal transduction pathways determined by KEGG analysis will provide further insight into future research directions of ncRNAs and mRNA.

![The KEGG enrichment analysis of the cis targeted genes of DElncRNA **(A)**, the trans targeted genes of DElncRNA **(B)**, DEmRNA **(C)**, hostgenes of DEcirRNA **(D)**, and targeted genes of DEmiRNA **(E)**. The abscissa GeneRatio represents the proportion of genes of interest in the pathway, and the ordinate represents each pathway. The size of the dots represents the number of genes annotated in the pathway, and the color of the dots represents the corrected *p* value of the hypergeometric test. **Abbreviation:** KEGG, Kyoto Encyclopedia of Genes and Genomes.](fphar-10-00798-g007){#f7}

Regulatory Network of ncRNAs and mRNA {#s3_8}
-------------------------------------

To explore the molecular mechanism of ncRNAs, a circRNA--miRNA--mRNA regulatory network and lncRNA--miRNA--mRNA network were constructed based on the theory of ceRNA. By using circRNA as a decoy, miRNA as the center, and mRNA as the target, the circRNA--miRNA--mRNA regulation network containing 437 mRNAs, 23 circRNAs, and 17 miRNAs was generated ([**Figure 8**](#f8){ref-type="fig"}). By using lncRNA as a decoy, miRNA as center, and mRNA as target, the lncRNA--miRNA--mRNA regulation network that contained 331 mRNAs, 24 lncRNAs, and 13 miRNAs was built ([**Figure 9**](#f9){ref-type="fig"}). In these two networks, different shapes represent different RNA types; red and green represent up- and down-regulation, respectively. Interestingly, circRNA (8:93786223\|93822563), ENST00000313807, and ENST00000449307 were all able to regulate LRG1 expression, through competitively binding with miR-5096. These results suggested that circRNAs and lncRNAs harbor miRNA response elements and play pivotal regulatory roles in the mechanisms of QUE in anti-CRC.

![The interaction network of circRNA--miRNA--mRNA. Red and green represent up- and down-regulation, respectively.](fphar-10-00798-g008){#f8}

![The interaction network of lncRNA--miRNA--mRNA. Red and green represent up- and down-regulation, respectively.](fphar-10-00798-g009){#f9}

Discussion {#s4}
==========

CRC is one of the most common types of malignant tumors, ranking as the second leading cause of cancer-induced death worldwide. Multiple lines of studies have demonstrated the efficacy of QUE in CRC ([@B11]; [@B37]; [@B9]), but the exact mechanism of its anti-tumor effects in CRC remains unclear. To the best of our knowledge, this is the first comprehensive report of lncRNA, mRNA, circRNA, and miRNA to reveal regulator pathways with regard to QUE-induced apoptosis in HCT-116 cells.

In general, our data confirmed that QUE could inhibit the proliferation and induce apoptosis of HCT-116 cells. With FC ≥ 2.0 and *p* value \< 0.05 thresholds, a total of 240 lncRNAs, 131 circRNAs, 83 miRNAs, and 1415 mRNAs with significant differential expression were identified in the QUE-treated cells compared with the untreated cells. We found that several DEmRNAs and DEmiRNAs may be connected with CRC. However, the great majority of DElncRNAs and DEcircRNAs were not known, mainly due to rarely related research. In addition, 12 dysregulated ncRNAs and mRNAs identified were selected for qRT-PCR validation, and the results confirmed the sequencing analysis findings to some extent. On the basis of the KEGG analysis, two significantly enriched pathways, PI3K-Akt and Ras signaling pathway, were participated by all four RNAs. Previous studies have reported that these two cancer-related pathways may be the possible molecular mechanisms of QUE in anti-CRC ([@B24]; [@B36]; [@B45]; [@B50]). Our research results further confirmed this possibility, more deeply, comprehensively, and systematically.

Firstly, we focused on the differentially expressed coding genes. The top 20 DEmRNAs were regarded as the most important ones involved in mechanism of QUE acting on CRC. Among them, pioneering studies demonstrated that their dysregulation may result in the progression of CRC, such as AZGP1 ([@B21]; [@B7]; [@B49]), APOBEC3G ([@B12]; [@B26]), BST2 ([@B34]), TRIM29 ([@B22]; [@B47]), and S100A4 ([@B8]; [@B13]). Our results first suggested that MAGEA6, TNFSF12-TNFSF13, ANK1, PRR15L, BAG6, CD79B, KRT20, CTD-2410N18.5, RP11-385D13.1, HLA-DRB1, TTYH1, TNFRSF6B, PPP1R1B, SMIM5, and PTGDS may also exert their functions. The KEGG pathway analysis indicated that QUE-responsive gene alterations in HCT-116 cells were significantly enriched in the MAPK signaling pathway, a widely known cancer-related pathway. LRG1, which enriched in the MAPK pathway, has been strongly associated with worse overall survival for CRC, and may be considered as an independent prognostic indicator for CRC ([@B25]; [@B51]; [@B55]; [@B52]). In this study, LRG1 was proved to be down-regulated in QUE-treated HCT-116 cells compared to the untreated HCT-116 cells. These investigations indicated that LRG1 might be a potential drug target of QUE acting on CRC by regulating the MAPK signaling pathway.

Subsequently, the effects of QUE on ncRNAss, including miRNAs, lncRNAs, and circRNAs, were evaluated in the current study. Previous studies indicated that miR-338-3p dysregulation may contribute to the progression of CRC ([@B48]). In our study, miR-338-3p was significantly up-regulated in HCT-116 cells treated with QUE, and was the top regulated ones. We suggested that miR-338-3p may be an important one participating in QUE's anti-CRC mechanism. Additionally, four DEmiRNAs were referred as the most likely candidate miRNA associated with the mechanism of QUE. Among these, the expression of miR-320b, miR-320c, and miR-320d was significantly lower in CRC tissues than in normal tissues ([@B30]). In our research, these three miRNAs were up-regulated in HCT-116 cells treated with QUE. These observations suggested that miR-320b, miR-320c, and miR-320d may play vital roles in anti-CRC mechanism of QUE. MiR-125b-2-3p, significantly down-regulated miRNA in CRC, was also pointed out as a novel diagnostic and prognostic biomarker in human CRC ([@B54]). Our data showed that miR-125b-2-3p was up-regulated in QUE-treated HCT-116 cells. These studies suggested that miR-125b-2-3p may play an important role in the anti-CRC mechanism of QUE. Furthermore, some DEmiRNAs, such as novel_miR_873, novel_miR_710, novel_miR_20, and novel_miR_885, were also found to be significantly different between CRC cells with and without treatment of QUE, which suggested that these miRNAs play an important role in the anti-CRC mechanism of QUE. The relationships between these genes and CRC were firstly reported.

We noticed that a significant GO term of DElncRNAs and their target gene were related with DNA repair. This phenomenon is very illuminating, given the importance of DNA repair and damage in cancer ([@B33]). Consistent with the results of GO analysis, KEGG pathway analysis also revealed that pathways associated with mismatch repair, nucleotide excision repair, and base excision repair were among the top regulated ones. From the result of the lncRNA--miRNA--mRNA network, we found that ENST00000313807 and ENST00000449307 were co-expressed with LRG1, which played important roles in anti-CRC mechanisms of QUE, through competitively binding with miR-5096. Additionally, MSTRG.13489.1, MSTRG.64442.1, MSTRG.128888.1, MSTRG.126191.1, ENST00000449307, ENST00000430883, ENST00000428222, MSTRG.71538.4, ENST00000434051, and MSTRG.211506.21 were identified to bind miR-338-3p competitively with its binding sites. None of these lncRNAs have been reported to be functional during CRC.

Increasing evidence indicate that circRNAs can influence miRNA activity as endogenous sponges and affect mRNA splicing and transcription by interacting with the Pol II complex in the nucleus ([@B41]; [@B46]). As many circRNAs failed to be allocated to functional modules, little public data about these circRNAs could be found. In this study, based on the constructed circRNA--miRNA--mRNA co-expression network, we observed that many circRNAs contained one or more miRNA binding sites. Thus, circRNA (8:93786223\|93822563) was able to interact with LRG1, through competitively binding with miR-5096. This competitively binding mode was similar with ENST00000313807 and ENST00000449307. Therefore, further study was deserved to reveal the interaction relationships of circRNA (8:93786223\|93822563)--miR-5096--LRG1 in QUE's action mechanism.

Although altered ncRNAs and mRNAs were identified and their possible roles in anti-CRC mechanisms of QUE were investigated, several limitations should be considered in interpreting our findings. Firstly, a previous study reported that maximum plasma concentrations of QUE after the ingestion of 100 mg were lower than 10 µM ([@B14]), and only one-tenth of the lower QUE concentration is used in this *in vitro* assays. Recently, the daily dose of QUE in a clinical study was up to 1250 mg for three consecutive days/week ([@B23]). Merging these results, one may speculate that those effective tissue levels could be attained. Thus, we selected relatively high concentrations of QUE to investigate its effects on the CRC cell line. In future studies, we could perform an analysis by exposing cells to lower QUE concentrations, aiming to investigate whether lower concentrations of QUE have anti-CRC efficacy and different impacts on gene expression profiles. Secondly, the analysis was only performed on HCT-116 cancer cells. Global ncRNA and mRNA changes in other CRC cell lines and CRC model animals treated with QUE should be also determined in further studies to more accurately reflect the anti-CRC mechanisms of QUE. Thirdly, RNA-sequence technology should be applied to unravel previously inaccessible transcriptome complexities, and because the functions of ncRNAs remain largely unknown, the comprehension of our data was not straightforward ([@B44]). Finally, further research should select more ncRNAs and mRNAs for sequencing data validation and observe whether the apoptotic process of HCT-116 cells will change by manipulating the expression of top nRNA and mRNA candidates. To solve this problem, further studies are now highly warranted.

Conclusion {#s5}
==========

In summary, changes in the coding and non-coding transcriptomes of HCT-116 cells without and with QUE intervention were identified, and combining it with bioinformatics analysis may provide a better understanding of the potential roles of miRNA, lncRNA, circRNA, and mRNA in CRC and QUE treatment. To better reveal the mechanism of QUE-mediated apoptosis in HCT-116 cells, we now need to conduct further experiments through manipulating the action of the top potential candidates in this study. Moreover, the corresponding roles and molecular mechanisms of these ncRNA and mRNA need to be further explored.
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